StemCells acquires key patents from University of Calgary
This article was originally published in Clinica
StemCells Inc of Newark, California has acquired a portfolio of US and Canadian patents with expiration dates as far out as 2024, which previously were licensed from the University of Calgary. The company will issue 139,548 shares of StemCells common stock to Neurospheres Holdings, the university's intellectual property holding company. The acquisition relieves StemCells of all milestone and royalty obligations under prior license agreements for products claimed by the patents, such as the company's proprietary purified human neural stem cells (HuCNS-SC).